16 results about "Intestinal mucosal barrier" patented technology

The present invention provides a nutritional composition comprising one or more of vitamin D, polydextrose and galacto-oligosaccharides in combination with a calcium source. The composition has the effect of improving the intestinal mucosal barrier including improving intestinal mucosal permeability, modulating expression of intercellular tight junction proteins, improving intestinal mucosal tissue structure and improving levels of markers of the intestinal mucosal barrier.

The application relates to the technical field of medicines, in particular to application of N-acetylneuraminic acid in preparation of medicines for preventing and / or treating ulcerative colitis. The application finds that N-acetylneuraminic acid can effectively prevent or treat ulcerative colitis and promote tissue repair by regulating macrophage metabolism, inhibiting glycolysis pathways and M1 type polarization, and simultaneously repairing intestinal mucosal barrier, thereby providing a safe, simple and clear mechanism of action new treatment strategy for clinic.

The application discloses application of forskolin and / or isoforskolin in preparation of a medicine for preventing and / or treating colitis, and belongs to the technical field of medicines.The medicine can significantly improve the disease phenotype of colitis, including relieving weight loss, reducing disease activity index score, improving colon length shortening and histopathological damage.The mechanism of action involves multiple targets: repairing intestinal mucosal barrier function, reducing local inflammation of the colon, and regulating intestinal flora balance, restoring the abundance of beneficial bacteria and inhibiting the proliferation of pathogenic bacteria.The application provides a candidate drug with anti-inflammatory, barrier repair and flora regulation functions for the treatment of colitis, and expands the medical use of forskolin or isoforskolin.

The application belongs to the technical field of biological medicine, and particularly relates to a medium-chain fatty acid composition for improving immunity of calves and a preparation method thereof. The medium-chain fatty acid composition for improving immunity of calves according to the application comprises, in terms of weight fractions, 20-30 parts of lactose, 5-10 parts of medium-chain fatty acid, 1-3 parts of mangiferin derivative, 0.5-2 parts of wedelolactone and 0.2-1 part of vitamin C. The mangiferin derivative according to the application can relieve local inflammatory reaction of the intestinal tract, repair the intestinal mucosal barrier damaged by stress, and enhance the non-specific immune capacity of the body. The wedelolactone according to the application forms a double synergy with the lactose and the medium-chain fatty acid, greatly improves the utilization efficiency of energy and nutrients, and thus promotes the growth and development of the calf. In addition, the wedelolactone can also synergize with the mangiferin derivative, maintains the intestinal health of the calf in the early weaning period, and significantly weakens the weaning stress impact.

This invention relates to the field of pharmaceutical technology, specifically to the application of porcine deoxycholic acid (HDCA) in the preparation of a drug for alleviating colitis. The dosage of HDCA is 50-200 mg / kg body weight / day. The colitis referred to is DSS-induced colitis, inflammatory bowel disease, or ulcerative colitis. Administration is by gavage. The drug alleviates colitis by promoting the proliferation of intestinal stem cells and / or repairing intestinal barrier function. This method can reverse the decrease in food intake and body weight in mice under DSS, reduce their disease activity index, and alleviate the problem of DSS-induced colon shortening in mice; simultaneously, HDCA also promotes the proliferation of intestinal stem cells, repairs intestinal permeability, and alleviates DSS-induced damage to the intestinal mucosal barrier function in mice. It can inhibit the expression of intestinal inflammation-related genes in mice, alleviating inflammatory complications. It helps to reshape the intestinal flora of mice, especially promoting Akkermansia colonization and alleviating intestinal barrier damage.

The application provides application of Elaeagnus conferta polysaccharide in preparation of a medicine for treating intestinal barrier related diseases, and relates to the technical field of natural medicine chemistry. The intestinal protection effect of the Elaeagnus conferta polysaccharide on a dextran sodium sulfate induced intestinal injury model of mice is investigated, and the research result shows that the Elaeagnus conferta polysaccharide can treat clinical symptoms such as diarrhea, enteritis and weight loss caused by intestinal barrier injury, significantly reduces disease scores, inhibits colonic tissue goblet cell necrosis, promotes secretion of mucin, increases expression of tight junction proteins, and enhances intestinal mucosal barrier function. As a widely planted fruit and a fruit loved by the public, the Elaeagnus conferta has the advantages of high safety and easy acquisition. It is expected to become an effective active ingredient source for resisting intestinal injury diseases, and has a broad market development prospect.

The application discloses application of Amomum tsao-ko extract in preparation of medicines for preventing and treating chronic alcoholic liver and intestinal injury, and belongs to the technical field of biotechnology. The extract is applied to prevention and / or treatment of alcoholic liver and intestinal injury and liver-intestinal axis disorder caused by long-term drinking, can reduce contents of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in blood plasma, improve liver and colon tissue pathological injury, repair intestinal mucosal barrier, restore liver tissue mitochondrial function and regulate expression of key factors of liver-intestinal axis; and the Amomum tsao-ko extract can effectively reduce the contents of AST and ALT in blood plasma of alcohol-induced alcoholic liver and intestinal injury model mice at a lower dose, significantly improve liver and intestinal tissue pathological injury, correct liver-intestinal axis function disorder and regulate expression of liver-intestinal axis related factors of liver tissue; the raw material of the application is from a natural product, and is convenient to collect and high in safety.

The present application relates to the field of biological medicine and functional food, and discloses a kind of nutrition composition based on marine shrimp peptide for anti-obesity and improving metabolic syndrome;Including: Chinese tube whip shrimp peptide active component and pharmaceutically acceptable adjuvant, the Chinese tube whip shrimp meat protein is used as raw material, and the Chinese tube whip shrimp meat protein is prepared by alkaline protease enzymolysis, and the Chinese tube whip shrimp meat protein contains peptide segment with molecular weight less than 1 kDa, and APPPPP, HPPPP and MPLPP can be detected.The pharmaceutical composition can reduce the weight and fat tissue weight under the state of obesity, improve dyslipidemia, abnormal liver function and liver steatosis, reduce oxidative stress level, improve intestinal mucosal barrier damage and intestinal permeability increase, and regulate intestinal flora structure change.The active component in the present application is clear in origin, and the preparation process is clear, has the synergistic effect from lipid metabolism regulation, liver protection to intestinal barrier improvement, and can be used for preparing medicine for preventing or treating obesity and improving metabolic syndrome.

The present application belongs to the technical field of livestock breeding feed additives, in particular to a Chinese herbal medicine compound additive for preventing and controlling piglet diarrhea in the teaching trough and the nursing stage and a preparation method thereof, the additive is composed of 35-50 parts of Chinese medicine active extract composition, 40-55 parts of wall material inclusion compound and 5-10 parts of functional adjuvant by weight fraction; the Chinese medicine active extract composition is prepared by extracting ten Chinese herbal medicines such as Huangqi, Huanglian and Baizhu, the wall material inclusion compound is a complex system of -cyclodextrin, chitosan and sodium alginate, the functional adjuvant is composed of microcrystalline cellulose, magnesium stearate and stevioside in proportion, and the finished product is a pH sensitive microcapsule particle; the additive does not contain antibiotics and high-dose zinc oxide, can realize the functions of synergistically inhibiting bacteria and resisting viruses, repairing intestinal mucosal barrier and regulating intestinal digestive function, effectively prevents and controls piglet diarrhea, and improves piglet feed intake and growth performance.

The application relates to the technical field of ulcerative colitis prevention and treatment, and particularly relates to application of avicularin in preparation of ulcerative colitis prevention and treatment drugs. Avicularin can effectively improve ulcerative colitis of mice caused by dextran sulfate sodium (DSS), can not only improve colon injury and reduce DAI index, but also can reduce expression of inflammatory cytokines and increase expression of intestinal mucosal barrier related proteins.

The application belongs to the field of biological medicine and microecological intervention technology, and relates to application of Bacillus coagulans T-21 in reducing ulcerative colitis combined with cognitive dysfunction. A dextran sodium sulfate (DSS) induced mouse ulcerative colitis combined with cognitive dysfunction model is established by taking a Bacillus coagulans T-21 strain as an active ingredient, and an intervention effect is evaluated. Results show that the Bacillus coagulans T-21 intervention can improve the cognitive related behavior performance and learning and memory ability of the model mice, thereby reducing ulcerative colitis related cognitive dysfunction. Meanwhile, the Bacillus coagulans T-21 intervention can increase the colon length, up-regulate the expression of tight junction proteins Occludin, Claudin-1 and Claudin-5 in colon tissue, improve the intestinal mucosal barrier damage, and down-regulate the expression levels of pro-inflammatory factors IL-1beta in colon tissue and IL-6 in hippocampus tissue, thereby reducing intestinal and central inflammatory reactions.

The application discloses application of L-phenylalanine in preparation of an intestinal inflammation treatment product, wherein the L-phenylalanine has a CAS number of 63-91-2, belongs to a natural amino acid, and has high safety; the product is a drug, a food or a feed additive; the application can treat inflammatory bowel disease, reduce intestinal inflammatory reactions, and promote intestinal mucosal repair and maintenance of intestinal mucosal barrier function, so that intestinal inflammation related clinical symptoms are improved.

The application discloses a bifidobacterium qis1821 with high indole-3-lactic acid yield and application thereof, and is characterized by being classified and named as bifidobacterium qis1821 Bifidobacterium bifidum , and is preserved in the China General Microbiological Culture Collection Center on May 13, 2026, with a preservation number of CGMCC No. 38669. The bifidobacterium qis1821 has the application in the preparation of high-yield indole-3-lactic acid products and antioxidants, and also has the application in the preparation of intestinal flora regulators. The bifidobacterium qis1821 has the characteristics of high indole-3-lactic acid yield, good tolerance in an artificial gastric juice and antioxidant performance, and can also produce lactic acid and other beneficial metabolites, so that the intestinal flora can be regulated, and the intestinal mucosal barrier function can be enhanced.

The present application relates to the technical field of biopharmaceuticals, and particularly relates to a siRNA targeting ADAM17 gene based on intestinal barrier repair and application thereof in improving visceral hypersensitivity of IBS. The siRNA silences ADAM17 expression, inhibits abnormal cleavage of IL-10 receptor alpha subunit (IL-10RA) on the membrane of intestinal epithelial cells, maintains the integrity of the membrane-bound IL-10 receptor, restores IL-10 protective signaling, up-regulates tight junction proteins such as ZO-1 and Occludin, reduces intestinal permeability, repairs intestinal mucosal barrier, and finally improves colorectal distension-induced pain threshold and relieves visceral hypersensitivity. Animal model experiments show that the siRNA can significantly reduce the expression of ADAM17 protein in the colon, improve the structure and function of the barrier, and increase the pain threshold, and has application prospects as a new molecular targeted treatment for IBS.

The present application relates to a kind of synbiotic preparation, comprising: probiotic or its bacterial lysate, fermentation product, wherein probiotic is one or more selected from the following group: Bifidobacterium, Streptococcus, Lactobacillus, Saccharomycete, Escherichia coli;Prebiotic is one or more selected from the following group: breast milk oligosaccharide, fructo-oligosaccharide, inulin, lactulose, galacto-oligosaccharide, soybean oligosaccharide, resistant dextrin, xylo-oligosaccharide, isomalto-oligosaccharide, chitooligosaccharide;And wall material;The probiotic or its bacterial lysate, fermentation product is coupled with prebiotic, and wall material is wrapped in the coupling product.The synbiotic preparation of the application is simple, no chemical drug or antibiotic component is added, can repair damaged intestinal mucosal barrier, reduce intestinal permeability, regulate immune balance, optimize flora structure, so as to more effectively treat colitis.In addition, it is convenient to use, easy to promote in farm.

This invention discloses a birch bark extract solubilizing formulation for the prevention and treatment of radiation enteritis and its preparation method, belonging to the field of pharmaceutical technology. The formulation includes birch bark extract, ethanol, and water. Poloxamer F68 is used as the solubilizing carrier, and the mass ratio of birch bark extract to poloxamer F68 is 1:(5-15). The solubilizing formulation is prepared through steps of ethanol co-dissolution, ultrasonic treatment, rotary evaporation to remove alcohol, and resolubilization with water. This invention effectively solves the technical bottlenecks of poor water solubility, insufficient dispersibility, and inadequate storage stability of birch bark extract. The prepared formulation is uniform and stable, significantly reducing the damage to the body caused by radiation enteritis, inhibiting intestinal inflammatory responses, and repairing the intestinal mucosal barrier. It can be used to prepare drugs for the prevention and treatment of radiation enteritis. Its preparation process is simple and controllable, with high pharmaceutical safety, and is suitable for industrial production.